SMARCB1 and cancer: Clinical trials of valemetostat in other cancer types (e.g., peripheral T-cell lymphoma, B-cell lymphoma, and tumors with SMARCB1 deficiency) and of two other dual inhibitors (HM97662 and HH2853) are underway704 (Table 1).